Eyegate Pharmaceuticals (EYEG) Stock: Flying On Clinical Update

Eyegate Pharmaceuticals Inc EYEG Stock NewsEyegate Pharmaceuticals Inc (NASDAQ: EYEG) is having an overwhelmingly strong start to the trading session this morning after announcing a clinical update. The update surrounded enrollment in a Phase 3 clinical trial, and the news was positive. Of course, the update led to excitement among investors, sending the stock on a run for the top. Today, we’ll talk about:

  • The clinical update;
  • what we’re seeing from EYEG as a result;
  • and what we’ll be watching for ahead.

EYEG Announces The Completion Of Patient Enrollment

As mentioned above, Eyegate Pharmaceuticals is having a strong day in the market today after announcing patient enrollment news surrounding a pivotal Phase 3 clinical trial. In a press release issued early this morning, the company announced the completion of patient enrollment for the pivotal Phase 3 clinical study of its EGP-437 combination product for the treatment of non-infectious anterior uveitis.

In the release, EYEG explained that non-infectious anterior uveitis is characterized by the inflammation of the anterior chamber of the eye. Symptoms of non-infectious anterior uveitis include redness, soreness and inflammation of the eye, blurring vision, sensitivity to light, and a small pupil, and when left untreated, could cause vision loss.




The trial that EYEG is working on at the moment is a double-masked, randomized, positive-controlled trial. In the trial, the company will assess the safety and efficacy of iontophorically-delivered EGP-437 in 250 patients with unilateral or bilateral non-infectious anterior segment uveitis. In the release, the company said that the primary efficacy endpoint of the trial surrounds the proportion of subjects with an anterior chamber cell count of zero at 14 days. In a statement, Stephen From, President and CEO at Eyegate, had the following to offer:

Completion of patient enrollment in this confirmatory Phase 3 clinical trial evaluating our unique EGP-437 combination product represents a major milestone for the company… Congratulations to our committed team of trial investigators and coordinators on this critical milestone. We expect top line data in the third quarter and, assuming positive data from this trial, we plan to submit a New Drug Application to the FDA in the first half of 2019.

What We’re Seeing From The Stock

As investors, one of the first lessons that we learn is that the news moves the market, and the news surrounding Eyegate Pharmaceuticals proved to be overwhelmingly positive. After all, with news that the Phase 3 pivotal trial surrounding EGP-437 has completed enrollment, the company is one step closer to making this treatment commercially available, should the trial go well and the regulatory authorities at the FDA agree. Nonetheless, it’s no surprise to see that the stock is making a run for the top in the market today. At the moment (10:54), EYEG is trading at $0.52 per share after a gain of $0.13 per share or 33.15% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on EYEG. In particular, we’re interested in following the story surrounding the company’s work with regard to EGP-437 and we’re excited to see the results of the pivotal Phase 3 clinical study. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Leave a Comment